Lei Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lei Li has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Jiyi Xu
The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, 5 Ankang Lane, Dewai Avenue, Xicheng District, Beijing 100088 China; Advanced lnnovation Center for Human Brain Protection, Capital Medical University, 10 Xi tou tiao, You An Men Wai, Fengtai District, Beijing 100069 China
2 shared publications - Tianyi Wang
The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, 5 Ankang Lane, Dewai Avenue, Xicheng District, Beijing 100088 China; Advanced lnnovation Center for Human Brain Protection, Capital Medical University, 10 Xi tou tiao, You An Men Wai, Fengtai District, Beijing 100069 China
2 shared publications - Bing-Xi Sun
Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), Beijing Key Laboratory for Big Data Innovative Application of Child and Adolescent Mental Disorders, National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing 100191, China
1 shared publication - Chao-Gan Yan
State Key Laboratory of Cognitive Science and Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China
1 shared publication - Duo Wang
Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), Beijing Key Laboratory for Big Data Innovative Application of Child and Adolescent Mental Disorders, National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing 100191, China
1 shared publication - Gang Wang
Beijing Key Laboratory of Intelligent Drug Research and Development for Mental Disorders; National Clinical Research Center for Mental Disorders, National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, China
1 shared publication
Latest Publications
- 27 February 2026
- Published by Elsevier in Neuroscience Letters
- Vol. 877, 138569
Proteomic profiling of the prefrontal cortex reveals Dysregulated Mitochondria-Metabolism-Synapse axis in a chronic Stress-Induced mouse model of depression
- 27 February 2026
- Published by Elsevier in Neuroscience Letters
- Vol. 877, 138569
Proteomic profiling of the prefrontal cortex reveals Dysregulated Mitochondria-Metabolism-Synapse axis in a chronic Stress-Induced mouse model of depression
- Open Access
- 15 July 2025
- Published by Elsevier in Brain Research Bulletin
- Vol. 229, 111466
Alterations in whole-brain white matter fiber networks in individuals with autism spectrum disorder after social skills training
- 15 July 2025
- Published by Elsevier in Brain Research Bulletin
- Vol. 229, 111466
Open AccessAlterations in whole-brain white matter fiber networks in individuals with autism spectrum disorder after social skills training
- 31 March 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 62 (8) , 9817-9828
The Role of Mitochondrial Dysfunction-Mediated Changes in Immune Cytokine Expression in the Pathophysiology and Treatment of Major Depressive Disorder
Recent studies have demonstrated an association between major depressive disorder (MDD) and both mitochondrial dysfunction and alterations in pro-inflammatory cytokine expression, suggesting that such changes may be key drivers of MDD pathogenesis. Mechanistically, changes in mitochondrial function are related to endoplasmic reticulum stress, reactive oxygen species production, oxidative phosphorylation, apoptosis, and disrupted calcium ion homeostasis, all of which trigger the activation of signaling cascades that affect the expression of pro-inflammatory cytokines, including tumor necrosis factor alpha, interleukin 1, interleukin 6, and interferons. Certain factors present in the gut microbiota ecosystem can influence communication between microorganisms and the brain through the neuroendocrine, immune, and autonomic nervous systems, thereby altering mitochondrial function and cytokine production. This review article explores the means through which mitochondria regulate immune cytokine expression and the role of mitochondrial dysfunction in the pathogenesis and treatment of MDD to provide new perspectives for the diagnosis of this disease and the development of novel therapeutic interventions with greater efficacy and improved safety profiles.
- 31 March 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 62 (8) , 9817-9828
The Role of Mitochondrial Dysfunction-Mediated Changes in Immune Cytokine Expression in the Pathophysiology and Treatment of Major Depressive Disorder
Recent studies have demonstrated an association between major depressive disorder (MDD) and both mitochondrial dysfunction and alterations in pro-inflammatory cytokine expression, suggesting that such changes may be key drivers of MDD pathogenesis. Mechanistically, changes in mitochondrial function are related to endoplasmic reticulum stress, reactive oxygen species production, oxidative phosphorylation, apoptosis, and disrupted calcium ion homeostasis, all of which trigger the activation of signaling cascades that affect the expression of pro-inflammatory cytokines, including tumor necrosis factor alpha, interleukin 1, interleukin 6, and interferons. Certain factors present in the gut microbiota ecosystem can influence communication between microorganisms and the brain through the neuroendocrine, immune, and autonomic nervous systems, thereby altering mitochondrial function and cytokine production. This review article explores the means through which mitochondria regulate immune cytokine expression and the role of mitochondrial dysfunction in the pathogenesis and treatment of MDD to provide new perspectives for the diagnosis of this disease and the development of novel therapeutic interventions with greater efficacy and improved safety profiles.